BSX stock | 2 billion buyback

 The company entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase, part of a $5 billion share repurchase program.

・The $2B The repurchase is expected to add about $0.02 to adjusted earnings per share in full-year 2026.

・BofA cited a changing medtech valuation environment and broader market concerns for the price target cut.

Shares of Boston Scientific (BSX) climbed 5% on Monday as investors cheered a flurry of corporate updates, including a major strategic investment in privately held MiRus and a $2 billion accelerated share repurchase program.

Separately, Bank of America lowered its price target on Boston Scientific stock to $68 from $105 while maintaining a ‘Buy’ rating, according to The Fly. The firm cited a changing medtech valuation environment and broader market concerns, such as the potential for inflation to rise after the war and the “data centers over healthcare” sentiment.